NASDAQ
22.76USD
+1.39 (+6.50%)
We have scored 68 news catalysts on PROCEPT BioRobotics Corporation (PRCT) over the past 12 months. The biggest single-day move next to one of them came Sep 4, 2026, when PRCT closed +6.5%: “PRCT INVESTOR DEADLINE: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit Before September 22, 2026”. Coverage across the window leans negative (average ticker sentiment −0.67). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Suppliers, customers, partners and competitors of PROCEPT BioRobotics Corporation, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for PRCT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
1.3B
P/E
—
EPS
—
Beta
0.90
52W range
16.665-41.51
Day range
21.06–22.84
Open
21.19
Prev close
21.37
Volume
1.3M
Avg volume
1.6M
Dividend
0.00
IPO
2021-09-15
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Analysts publish price targets on PRCT, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $19 to $30
as of 2026-09-01
The market is within 4% of the median target — broadly agreeing with the analysts.
The reconstruction
The price sits at the 50th percentile of published models, broadly endorsing the middle of the analyst set and explicitly rejecting the 18-42% upside offered by four bull cases.
What the disagreement turns on
Does the 30% sequential drop in U.S. handpiece sales represent a permanent pull-forward of demand that leaves the business impaired, or a temporary inventory glut that clears to allow a return to organic growth? Unit volume data can measure the trajectory, but it cannot definitively separate true procedure demand from channel stuffing.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $21.20 on 2026-09-01 — the quote has since moved +7%, so read this as a record of what was priced in then, not now.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about PROCEPT BioRobotics Corporation — not a sector bucket. Click an edge to see the articles that established the link.
